Satsuma Pharma's migraine drug fails in late-stage study (updated)

Satsuma Pharmaceuticals

14/11/2022 12:19

(Adds share movement, background)
       Nov 14 (Reuters) - Satsuma Pharmaceuticals Inc  STSA.O 
said on Monday its experimental migraine drug failed to meet the
main goals of a late-stage trial.
    The drug, STS101, was not statistically significant in
improving key measures such as freedom from pain and other
bothersome symptoms, when compared to placebo at two hours
post-administration, the company said.
    Satsuma also said it does not plan to invest in
commercializing STS101, and will actively explore alternatives
to maximize value for shareholders while minimizing cash
expenditures. 
    Shares of the company fell 77.3% to 92 cents before the
opening bell.
 (Reporting by Manas Mishra and Khushi Mandowara in Bengaluru;
editing by Uttaresh.V)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))